Everything below concerns deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
A 2017 literature review indicated there are numerous potential carcinogens of colorectal tissue in red meat, particularly those in processed red meat products, such as N-nitroso compounds, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic amines (HCAs). Cooking meat with "high-temperature methods, such as pan frying or grilling directly over an open flame", also causes formation of PAHs and HCAs.
== History == Zalsupindole was first described in the scientific literature by David E. Olson and colleagues in 2021. It was developed by Olson's lab at the University of California, Davis and at his company Delix Therapeutics. The drug was first synthesized in 2019. It was initially described under the name AAZ-A-154 and then by the name DLX-001 before receiving the name zalsupindole.
The 800-page "Doping in Germany from 1950 to today" study details how the West German government helped fund a wide-scale doping programme. West Germany encouraged and covered up a culture of doping across many sports for decades. Clemens Prokop, head of Germany's athletics federation, told Reuters Television in an interview, "It is a bit of a problem that there is a short version that has been published and that names have not been named." Immediately after the 1954 FIFA World Cup Final, rumors emerged that the West German team had taken performance-enhancing substances. Several members of the team fell ill with jaundice, presumably from a contaminated needle. Members of the team later claimed they had been injected with glucose, and the team physician Franz Loogen said in 2004 that the players had only been given Vitamin C before the game. A Leipzig University study in 2010 posited that the West German players had been injected with the banned substance methamphetamine. According to the German Olympic Sports Association (DOSB), doping was common in the West German athletes of the 1980s. West German heptathlete Birgit Dressel died at age 26 due to sudden multiple organ failure, triggered at least in part by long-term steroid abuse. In the newly emerging doping discussion in 2013 after submission of the final report of the anti-doping commission, the former German sprinter Manfred Ommer accused the Freiburg physician Armin Klümper: "Klümper was the largest doper on this planet."
=== Causality === The causality theory suggests that certain types of substance use may causally lead to mental illness. There is strong evidence that using cannabis can produce psychotic, including cannabis-induced psychotic disorder, and affective experiences. When it comes to persisting effects, there is a clear increase in the incidence of psychotic outcomes in people who had used cannabis, even when they had used it only once. More frequent use of cannabis strongly augmented the risk for psychosis. The evidence for affective outcomes is less strong. However, this connection between cannabis and psychosis does not prove that cannabis causes psychotic disorders. The causality theory for cannabis has been challenged as despite explosive increases in cannabis consumption over the past 40 years in western society, the rate of schizophrenia (and psychosis in general) has remained relatively stable.
Hydrogen peroxide is a chemical compound with the formula H2O2. In its pure form, it is a very pale blue liquid; however, at lower concentrations, it appears colorless due to the faintness of the blue coloration. The molecule hydrogen peroxide is asymmetrical and highly polarized. Its strong tendency to form hydrogen bond networks results in greater viscosity compared to water. It is used as an oxidizer, bleaching agent, and antiseptic, usually as a dilute solution (3%–6% by weight) in water for consumer use and in higher concentrations for industrial use. Concentrated hydrogen peroxide, or "high-test peroxide", decomposes explosively when heated and has been used as both a monopropellant and an oxidizer in rocketry. Hydrogen peroxide is a reactive oxygen species and the simplest peroxide, a compound having an oxygen–oxygen single bond. It decomposes slowly into water and elemental oxygen when exposed to light, and rapidly in the presence of organic or reactive compounds. It is typically stored with a stabilizer in a weakly acidic solution in an opaque bottle. Hydrogen peroxide is found in biological systems including the human body. Enzymes that use or decompose hydrogen peroxide are classified as peroxidases.
Sources: en.wikipedia.org
Sucrose is used in prepared foods (e.g., cookies and cakes), is added to commercially available ultra-processed food and beverages, and is used as a sweetener for foods (e.g., toast and cereal) and beverages (e.g., coffee and tea). Globally, on average, a person consumes about 24 kilograms (53 pounds) of sugar each year. North and South Americans consume up to 50 kg (110 lb), and Africans consume under 20 kg (44 lb). The use of added sugar in food and beverage manufacturing is a concern for elevated calorie intake, which is associated with an increased risk of several diseases, such as obesity, diabetes and cardiovascular disorders. In 2015 the World Health Organization recommended that adults and children should reduce their intake of free sugars to less than 10% of their total energy intake, encouraging a reduction to below 5%.
Shaun Slater, a Bromley councillor who tweeted that it was "more likely" a rape victim was a prostitute whose "punter... didn't pay", is expelled from the Conservative Party. 16 April – Around 600 Amazon workers based in Coventry and belonging to the GMB trade union begin a three-day strike over pay. 17 April – Prime Minister Rishi Sunak announces a review of the "core maths content" taught in England's schools, with the establishment of a panel to conduct the review. 24 April – The publishers of Big Issue North announce it is to cease publication in May, citing rising costs and reduced footfall in town centres. 25 April – South West Water implements a hosepipe ban for large parts of Devon in an attempt to replenish water levels at the Roadford Reservoir ahead of the summer. 26 April – West Midlands Police launch a murder inquiry after a man is stabbed near Queensbridge School in Kings Heath. The next day 2 People are arrested. The Royal College of Midwives announces that its members have voted to accept the government's pay offer for NHS workers in England. 28 April – Members of the Unite union, mostly ambulance workers and junior healthcare staff, reject the UK government's 5% pay offer for NHS workers in England. The offer is rejected by around half of the 55% who voted. The 5% NHS England pay offer is backed by the GMB union. Four teaching unions in England – the National Education Union, NASUWT, National Association of Head Teachers and the Association of School and College Leaders – announce plans to co-ordinate strike action.
With the Regents of the University of California still holding their (earlier) view that their university's Charter precluded any commercial activity, the Regents and Robertson eventually came to the extraordinary (at the time) arrangement (UC.5) of creating an external-to-the-university entity to manage the patent and "apply any unexpended balance of such proceeds, profits or returns to research work in Medicine and preferably in the Physiology, Chemistry and Pathology of Growth either under the auspices of the University of California or otherwise ... [or] such research work be conducted in part in Australia, either under the auspices of some institution of learning there or otherwise". Robertson and five others from the University of California formed the entity's first Board of Directors: Herbert McLean Evans (Professor of Anatomy), Frederick Parker Gay (Professor of Pathology), T. Brailsford Robertson (Professor of Biochemistry and Pharmacology), Carl Louis August Schmidt (Research Assistant in Pathology), and George Hoyt Whipple (Director of the Hooper Foundation for Medical Research and Professor of Research Medicine); and, once the Board of Directors had been appointed, the university granted a five year exclusive license in September 1917 to the H. K. Mulford Company "to manufacture and sell the compound known as Tethelin at its factory in the City of Philadelphia, State of Pennsylvania". "In 1923, by the end of Mulford's five-year contract, the university's royalties on sales of tethelin amounted to only $272.47" (CW.1, p. 35).
Richmond-Bridgeport MLA Teresa Wat claims Findlay made “unfounded accusations about me, including remarks that called my allegiance to Canada into question,” stating she "cannot continue to sit in a caucus led by someone who has questioned my loyalty without evidence and, when given the opportunity to correct the record, has failed to do so.” Courtenay-Comox MLA Brennan Day issued a statement criticizing Findlay's leadership, writing "I have lost confidence in the judgement, conduct, and ethical standards of her leadership and those she has chosen to surround herself with." Abbotsford South MLA Bruce Banman, the first MLA to cross the floor and join John Rustad as a Conservative, wrote "person after person has informed me they have decided that our new leader is unelectable," instead he is "joining an ever increasing number of MLAs to sit as an independent MLA in the BC Legislature". Banman also wrote he "would encourage my fellow MLAs regardless of political affiliation to join me." Boundary-Similkameen MLA Donegal Wilson cited Findlay's hiring of "Alberta separatist[s]" as the reason for her resignation, along with Findlay's inability to "bring Conservatives back together.” MLAs Ian Paton of Delta-South, Peter Milobar of Kamloops Centre, Rosalyn Bird of Prince George-Valemount, Áʼa꞉líya Warbus of Chilliwack-Cultus Lake, Scott McInnes of Columbia River-Revelstoke, and Linda Hepner of Surrey-Serpentine River also announced their resignation from the party. In September 2026, Findlay removed three MLAs from the Conservative caucus for questioning her leadership.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.